Dirk Blom
- Surgery top 0.2%
- Lipoproteins and Cardiovascular Health 122
-
- Diabetes, Cardiovascular Risks, and Lipoproteins 41
- Hormonal Regulation and Hypertension 6
- Cancer Research top 1%
- Cancer, Lipids, and Metabolism 35
-
- Lipid metabolism and disorders 27
- Economics and Econometrics top 0.5%
- Health Systems, Economic Evaluations, Quality of Life 31
- Pharmaceutical Economics and Policy 21
-
- Chronic Lymphocytic Leukemia Research 5
- Co-authors
- Frederick J. RaalScott M. WassermanA. David MaraisRobert C. ScottEvan A. SteinMichael J. KorenDaniel GaudetChristie M. Ballantyne
- Journals
- Journal of clinical lipidology (19 papers)Atherosclerosis (14 papers)Circulation (9 papers)
- Partner nations
- South AfricaUnited StatesFrance
In The Last Decade
Dirk Blom
148 papers receiving 7.9k citations
Hit Papers
Peers
Comparison fields: 5 of 124
- Surgery 6.3k
- Endocrinology, Diabetes and Metabolism 2.2k
- Cancer Research 1.6k
- Cardiology and Cardiovascular Medicine 2.0k
- Economics and Econometrics 1.9k
Countries citing papers authored by Dirk Blom
This map shows the geographic impact of Dirk Blom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Blom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Blom more than expected).
Fields of papers citing papers by Dirk Blom
This network shows the impact of papers produced by Dirk Blom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Blom. The network helps show where Dirk Blom may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Dirk Blom, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 6 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 0 | |
| 6 | 2023 | 1 | |
| 7 | 2020 | 4 | |
| 8 | 2016 | 0 | |
| 9 | 2015 | 2 | |
| 10 | Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for, or at low risk for, diabetes mellitus | 2015 | 6 |
| 11 | ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiabreakdown → | 2015 | 418 |
| 12 | Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialbreakdown → | 2014 | 553 |
| 13 | Abstract 16516: Sustained LDL-C Lowering and Stable Hepatic Fat Levels in Patients With Homozygous Familial Hypercholesterolemia Treated With the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide: Results of an Ongoing Long-Term Extension Study | 2013 | 11 |
| 14 | Abstract 17396: Apheresis Treatment does not Affect the Lipid-Lowering Efficacy of Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia | 2012 | 3 |
| 15 | 2012 | 1 | |
| 16 | Familial hypercholesterolaemia : CPD article | 2011 | 1 |
| 17 | New therapeutic developments in lipidology | 2009 | 1 |
| 18 | Abstract 1077: A Phase III Study of Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide (AEGR-733) in Patients With Homozygous Familial Hypercholesterolemia: Interim Results at 6 Months | 2009 | 4 |
| 19 | A clinical approach to dyslipidaemia | 2009 | 0 |
| 20 | 2008 | 11 |
About Dirk Blom
Dirk Blom is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cancer Research, having authored 159 papers that have together received 8.1k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (122 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (41 papers), Cancer, Lipids, and Metabolism (35 papers), Health Systems, Economic Evaluations, Quality of Life (31 papers), Lipid metabolism and disorders (27 papers), Pharmaceutical Economics and Policy (21 papers), Hormonal Regulation and Hypertension (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). The work is most often cited by research in Surgery (6.3k citations), Endocrinology, Diabetes and Metabolism (2.2k citations) and Cancer Research (1.6k citations). Dirk Blom has collaborated with scholars based in South Africa, United States and France. Frequent co-authors include Frederick J. Raal, Scott M. Wasserman, A. David Marais, Robert C. Scott, Evan A. Stein, Michael J. Koren, Daniel Gaudet, Christie M. Ballantyne, Marc S. Sabatine and Robert P. Giugliano. Their work appears in journals such as Journal of clinical lipidology, Atherosclerosis, Circulation, Journal of the American College of Cardiology and Atherosclerosis Supplements.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.